Open AccessAdjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disorders.
Author(s) -
Howard E. Gendelman,
Harris A. Gelbard
Publication year - 2014
Publication title -
current opinion in hiv and aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.901
H-Index - 64
eISSN - 1746-6318
pISSN - 1746-630X
DOI - 10.1097/coh.0000000000000111
Subject(s) - neurocognitive , medicine , neuroinflammation , adjunctive treatment , disease , intensive care medicine , bioinformatics , psychiatry , cognition , biology
We are pleased to review current and future strategies being developed to modulate neuroinflammation while reducing residual viral burden in the central nervous system. This has been realized by targeted long-acting antiretroviral nano and adjunctive therapies being developed for HIV-infected people. Our ultimate goal is to eliminate virus from its central nervous system reservoirs and, in so doing, reverse the cognitive and motor dysfunctions.